FDA panel backs first-in-class cholesterol drug

GAITHERSBURG, Md. (AP) -- Federal health advisers on Tuesday recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce heart attacks....

Read the whole article on AP Health

More from AP Health